Phase 2 N=12 Treatment

A Safety Study of Intravitreal PP-001 in Patients With Chronic, Non-Infectious Uveitis

Non-infectious Uveitis

Bottom Line

View on ClinicalTrials.gov: NCT03634475 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Oct 2024

Primary outcome: Primary: Evaluation of Safety and Tolerability by Determining Treatment Emergent Adverse Events — 12 Participants

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: PP-001 (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Panoptes Pharma GmbH
Primary completion: Nov 2018

Outcome Measures

Outcome	Result	p-value
PRIMARY Evaluation of Safety and Tolerability by Determining Treatment Emergent Adverse Events	12	—

Summary

In this study, PP-001 is assessed for safety and efficacy in patients diagnosed with non-infectious chronic uveitis. PP-001 is a novel small molecule that inhibits a specific enzyme (Dihydroorotate Dehydrogenase) and has shown pre-clinical efficacy in treatment of non-infectious uveitis. PP-001 will be administered to participants as a single intravitreal injection in ascending doses.

Eligibility Criteria

Inclusion Criteria

Male or female patients at the age of 18 years or older who have diagnosis of chronic, posterior uveitis, intermediate uveitis or panuveitis

Exclusion Criteria

Patients receiving specific medication/interventions as specified per protocol
Pregnant or nursing patients

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03634475). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.